All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the Lymphoma Coalition.
TRANSLATE
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma Hub is an independent medical education platform, sponsored by Roche, AbbVie, BeOne, Miltenyi Biomedicine, Thermo Fisher, Nurix Therapeutics and Caribou Biosciences and supported through independent educational grants from Incyte, Bristol Myers Squibb, Pfizer and Takeda Pharmaceuticals U.S.A., Inc. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View lymphoma & CLL content recommended for you
ASH 2022
25 Mar 2023
Revisit this:
🎥 #ASH22 | The Lymphoma Hub spoke to Hun Lee, MD Anderson Cancer Centre, Texas, US. We asked about the benefits of targeting ROR-1 with zilovertamab in patients with MCL and CLL.
Click here to see the full video 👉 https://t.co/EBsU27UY4d. #Lymsm
🎥 #ASH22 | The Lymphoma Hub spoke to Hun Lee, MD Anderson Cancer Centre, Texas, US. We asked about the benefits of targeting ROR-1 with zilovertamab in patients with MCL and CLL.
Click here to see the full video 👉 https://t.co/EBsU27UY4d. #Lymsm
15 Mar 2023
Revisit this:
🎥 #ASH22 | The Lymphoma Hub spoke with Veit L. Buecklein, Ludwig-Maximilians-Universitat, Munich, DE. We asked, What factors explain inferior survival for EU vs US patients with DLBCL after CAR T-cell therapy? 👉 https://t.co/NWnOhmOgU9. #Lymsm
🎥 #ASH22 | The Lymphoma Hub spoke with Veit L. Buecklein, Ludwig-Maximilians-Universitat, Munich, DE. We asked, What factors explain inferior survival for EU vs US patients with DLBCL after CAR T-cell therapy? 👉 https://t.co/NWnOhmOgU9. #Lymsm
10 Mar 2023
What are the outcomes of patients with aggressive B-cell lymphomas following CAR T-cell failure? Check out our summary of the DESCAR-T analysis and a follow-up analysis of the late CAR T-cell failure cohort, presented by Erbella during #ASH22 👉 https://t.co/hHIHOE3oB6.
#lymsm
#lymsm
6 Mar 2023
Revisit this:
🎥 #ASH22 | The Lymphoma Hub spoke to @AdrianMinson, Peter MacCallum Cancer Centre, Melbourne, AU. We asked, Can we combine targeted therapy with CAR T-cells in MCL? Click here to see what was said 👇 https://t.co/dOChNVAZJD.
#Lymsm
🎥 #ASH22 | The Lymphoma Hub spoke to @AdrianMinson, Peter MacCallum Cancer Centre, Melbourne, AU. We asked, Can we combine targeted therapy with CAR T-cells in MCL? Click here to see what was said 👇 https://t.co/dOChNVAZJD.
#Lymsm
1 Mar 2023
As part of #ASH22, @LiaPalomba presented results from the ongoing phase I/II BRUIN trial of pirtobrutinib in heavily pretreated patients with R/R Waldenstrom’s macroglobulinemia.
Check out the full visual abstract here 👉 https://t.co/GaW2po4LVk. #lymsm
Check out the full visual abstract here 👉 https://t.co/GaW2po4LVk. #lymsm
28 Feb 2023
Promising outcomes from novel treatment combinations in patients with R/R MCL were presented by @AdrianMinson, @MJerkeman and @JacobSoumerai at #ASH22. Check out our summary here 👉 https://t.co/ZgrafxN8nv. #lymsm
24 Feb 2023
Revisit this:
🎥 #ASH22 | The Lymphoma Hub spoke with Andrew Davies, University of Southampton, Southampton, UK. We asked, Can frontline treatment of DLBCL be improved by combining novel agents with R-CHOP? Click here to see what he said 👉 https://t.co/VaTPEhrk0Q. #lymsm
🎥 #ASH22 | The Lymphoma Hub spoke with Andrew Davies, University of Southampton, Southampton, UK. We asked, Can frontline treatment of DLBCL be improved by combining novel agents with R-CHOP? Click here to see what he said 👉 https://t.co/VaTPEhrk0Q. #lymsm
20 Feb 2023
🎥 #ASH22 | The Lymphoma Hub spoke with Hun Lee, MD Anderson Cancer Centre, Texas, US. We asked about improving safety and efficacy with brentuximab vedotin, nivolumab, and AD in advanced-stage classic Hodgkin lymphoma.👉 https://t.co/IHQxh2NVyd. #lymsm
16 Feb 2023
🎥 #ASH22 | The Lymphoma Hub spoke with @NEpperla, Ohio State University, Columbus, US. We asked, How robust is POD24 as a predictor of survival in indolent lymphomas?
Click here to see what was said 👉 https://t.co/9ZFZvSFzh4.
LINK #lymsm
Click here to see what was said 👉 https://t.co/9ZFZvSFzh4.
LINK #lymsm
13 Feb 2023
For patients with Richter transformation, there remains an unmet need for safe & efficacious clinical therapies. Data presented at #ASH22 highlighted two drugs that may lead to effective therapeutic options for these patients. Read about it here 👉 https://t.co/hZP3k83Fm6. #lymsm
13 Feb 2023
RT @lymphomahub: 🎥 #ASH22 | The Lymphoma Hub spoke with Won Seog Kim, Sungkyunkwan University, Seoul, KR. We asked, What do the ELM-2 resul…
10 Feb 2023
🎥 #ASH22 | The Lymphoma Hub spoke with Won Seog Kim, Sungkyunkwan University, Seoul, KR. We asked, What do the ELM-2 results tell us about the efficacy of odronextamab for R/R DLBCL?
Click here to see what was said 👉 https://t.co/jB2ZU1ocmn.
LINK #lymsm
Click here to see what was said 👉 https://t.co/jB2ZU1ocmn.
LINK #lymsm
7 Feb 2023
Promising outcomes of novel frontline treatment combinations (bortezomib+R-CHOP and glofitamab+R-CHOP) in patients with DLBCL were presented at the oral abstract session of #ASH22.
Check out our summary here 👉 https://t.co/yfdA55GIEV. #lymsm
Check out our summary here 👉 https://t.co/yfdA55GIEV. #lymsm
2 Feb 2023
📖 We summarize recent data from three trials presented during #ASH22 on bispecific antibodies for patients with previously untreated and R/R follicular #lymphoma.
Read more here: 👉 https://t.co/VxSR1qNnl3. #lymsm
Read more here: 👉 https://t.co/VxSR1qNnl3. #lymsm
30 Jan 2023
🎥 #ASH22 | The Lymphoma Hub spoke to Hun Lee, MD Anderson Cancer Centre, Texas, US. We asked about the benefits of targeting ROR-1 with zilovertamab in patients with MCL and CLL.
Click here to see the full video 👉 https://t.co/03FkOxBNbF. #Lymsm
Click here to see the full video 👉 https://t.co/03FkOxBNbF. #Lymsm
27 Jan 2023
Risk profiling of previously untreated patients with DLBCL from the POLARIX study, using ctDNA analysis, was presented at #ASH22. Read our summary here: 👉 https://t.co/Ez5qwmk6RJ #lymsm
23 Jan 2023
@GeraldIllerhaus presented the promising outcomes from the phase III MATRix/IELSG43 trial of consolidative HDC-ASCT versus non-myeloablative immunochemotherapy in patients with primary CNS lymphoma at the LBA session of #ASH22. #lymsm
Click here 👉 https://t.co/B9ejAXWfyI.
Click here 👉 https://t.co/B9ejAXWfyI.
20 Jan 2023
As part of the plenary scientific session at #ASH22, Martin Dreyling presented an update from the phase III TRIANGLE trial of frontline ibrutinib with/without ASCT vs SOC in younger patients with MCL.
Check out our summary here 👉 https://t.co/94TlGEL6uA. #lymsm
Check out our summary here 👉 https://t.co/94TlGEL6uA. #lymsm
18 Jan 2023
🎧 #ASH22 | The Lymphoma Hub spoke to @gilles_salles, @MSKCancerCenter. We asked for an update on the SYMPHONY 1 trial of tazemetostat, lenalidomide, and rituximab in patients with R/R follicular lymphoma. Click here to hear what was said 👉 https://t.co/d7dHWJeuU6,
#Lymsm
#Lymsm
16 Jan 2023
Final results from the phase III ALPINE trial of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL were presented by Jennifer Brown as part of the late-breaking abstracts session of #ASH22.
Check out our summary here 👉 https://t.co/qZsrNXG4ID. #lymsm
Check out our summary here 👉 https://t.co/qZsrNXG4ID. #lymsm
13 Jan 2023
🎧 #ASH22 | The Lymphoma Hub spoke to @chanyooncheah, University of Western Australia, Perth, AU. We asked for an update on novel therapies in CLL.
Click here to listen to the podcast 👉 https://t.co/PDvepIsJXH.
#Lymsm
Click here to listen to the podcast 👉 https://t.co/PDvepIsJXH.
#Lymsm
9 Jan 2023
🎥 #ASH22 | The Lymphoma Hub spoke to @AdrianMinson, Peter MacCallum Cancer Centre, Melbourne, AU. We asked, Can we combine targeted therapy with CAR T-cells in MCL? Click here to see what was said 👇 https://t.co/9JuPqTo3rW.
#Lymsm
#Lymsm
5 Jan 2023
🎧 #ASH22 | The Lymphoma Hub spoke to @pebarba, @vallhebron. We asked, What are the CAR T-cell therapies on the horizon for lymphoma?
Click here to see what was said: https://t.co/kceW4Zx0nx.
#Lymsm
Click here to see what was said: https://t.co/kceW4Zx0nx.
#Lymsm
22 Dec 2022
🎥 #ASH22 | The Lymphoma Hub spoke with Veit L. Buecklein, Ludwig-Maximilians-Universitat, Munich, DE. We asked, What factors explain inferior survival for EU vs US patients with DLBCL after CAR T-cell therapy? Click here to see what he said 👉 https://t.co/kVBELn118r. #Lymsm
19 Dec 2022
🎥 #ASH22 | The Lymphoma Hub spoke with Andrew Davies, University of Southampton, Southampton, UK. We asked, Can frontline treatment of DLBCL be improved by combining novel agents with R-CHOP? Click here to see what he said 👉 https://t.co/8BGISX3nF8. #lymsm
14 Dec 2022
We hope you enjoyed following our live updates and congress coverage from #ASH22!
Keep an eye on our socials for post-congress key points and insights!
#hematology #medicalcongress #cancerresearch #cancerawareness #medicaleducation #lymsm
Keep an eye on our socials for post-congress key points and insights!
#hematology #medicalcongress #cancerresearch #cancerawareness #medicaleducation #lymsm
13 Dec 2022
RT @MPN_Hub: CONGRESS | #ASH22
Drew Weissman, @WeissmanLab outlines the history of mRNA concluding with the development of the COVID-19 mRN…
Drew Weissman, @WeissmanLab outlines the history of mRNA concluding with the development of the COVID-19 mRN…
13 Dec 2022
RT @MM_Hub: CONGRESS | #ASH22
@profshanecrotty of the @ljiresearch institute speaks on SARS-CoV-2 and vaccinations in terms of immune respo…
@profshanecrotty of the @ljiresearch institute speaks on SARS-CoV-2 and vaccinations in terms of immune respo…
13 Dec 2022
#ASH22 LBA | Final analysis of ALPINE presented by Jennifer Brown @DanaFarber. Zanubrutinib shows superior ORR & PFS, and favourable safety profile compared with ibrutinib for R/R CLL/SLL. IRC 2yr PFS 79.5% vs 67.3% overall, 77.6% vs 55.7% in pts with del(17p)/TP53mut #lymsm
13 Dec 2022
#ASH22 LBA presented by @GeraldIllerhaus @KlinikumStutt on the MATRix/IELSG43 trial. Outcomes were significantly better after consolidation with HDC-ASCT than with non-myeloablative CIT (R-DeVIC) in PCNSL #lymsm #lymphoma
13 Dec 2022
CONGRESS | #ASH22
@DrMDavids, @DanaFarber discussed lisaftoclax in pts with #CLL and #SLL. Grade 3/4 neutropenia was common in monotherapy and in combination. No DLTs were observed. The best response was seen in the lisa + acalabrutinib cohort, with an ORR of 98% in R/R pts.
@DrMDavids, @DanaFarber discussed lisaftoclax in pts with #CLL and #SLL. Grade 3/4 neutropenia was common in monotherapy and in combination. No DLTs were observed. The best response was seen in the lisa + acalabrutinib cohort, with an ORR of 98% in R/R pts.
13 Dec 2022
CONGRESS | #ASH22
@jamesblachly, @OhioState presented early results from a study of MS-553, a highly selective PKC β inhibitor. Enrolled pts had #CLL or #SLL and were heavily pretreated. MTD was not reached. 48% of pts achieved PR/PRL with MS-553 monotherapy.
#lymsm #hematology
@jamesblachly, @OhioState presented early results from a study of MS-553, a highly selective PKC β inhibitor. Enrolled pts had #CLL or #SLL and were heavily pretreated. MTD was not reached. 48% of pts achieved PR/PRL with MS-553 monotherapy.
#lymsm #hematology
13 Dec 2022
CONGRESS | #ASH22
Veit Buecklein, @GeneCenter_LMU discussed outcome differences after CAR-T in US vs EU pts. EU pts generally had worse survival outcomes. Time to transfusion was a mean of 66 days in EU vs 50 days in US. There were no sig differences in toxicity between cohorts.
Veit Buecklein, @GeneCenter_LMU discussed outcome differences after CAR-T in US vs EU pts. EU pts generally had worse survival outcomes. Time to transfusion was a mean of 66 days in EU vs 50 days in US. There were no sig differences in toxicity between cohorts.
13 Dec 2022
CONGRESS | #ASH22 | Poster
Kris Richardson, @DanaFarber shared a poster on MYD88 and CXCR4 in WM. Using a multi-omic approach, expression of certain biomarkers was found to predict time to response with ibrutinib and correlated with long-term PFS.
#lymsm #medicalcongress
Kris Richardson, @DanaFarber shared a poster on MYD88 and CXCR4 in WM. Using a multi-omic approach, expression of certain biomarkers was found to predict time to response with ibrutinib and correlated with long-term PFS.
#lymsm #medicalcongress
13 Dec 2022
CONGRESS | #ASH22 @GHUMondor presents final analysis of the phase III ORACLE study of azacytidine in pts with R/R angioimmunoblastic T-cell #lymphoma. The primary endpoint was not met, however the drug showed a favorable safety profile and was associated with prolonged OS. #lymsm
13 Dec 2022
CONGRESS| #ASH22 @gilles_salles @MSKCancerCenter presents phase Ib results of the SYMPHONY-1 trial of tazemetostat + R2 in patients with R/R #FL. The data shows a manageable safety profile, with no new safety signals. Efficacy was high, regardless of mutation status.
#lymsm
#lymsm
12 Dec 2022
CONGRESS | #ASH22 @MaurerStats @MayoClinic discusses the rigorously developed FLIP24 international prognostic model. The model provides an individual risk score at diagnosis for the likelihood of experiencing an event within 24 months from starting IC.
#lymsm #medicalcongress
#lymsm #medicalcongress
12 Dec 2022
CONGRESS | #ASH22 @MelanicjMD @NCIResearchCtr shares data on the ViPOR regimen in patients with R/R #FL. The combination appears to be safe and effective in this patient group. ORR=100%, CR=79%. MRD was predictive of PFS in PET CR pts at EOT.
#lymsm #medicalcongress
#lymsm #medicalcongress
12 Dec 2022
CONGRESS | #ASH22
Anthony Mato, @MSKCancerCenter reported updated #CLL and #SLL results from the BRUIN study of pirtobrutinib. ORR in pts who previously received a BTKi was 74%. 2% of pts discontinued due to TEAE. 12mo estimated PFS rate was 68%.
#lymsm #medicalcongress
Anthony Mato, @MSKCancerCenter reported updated #CLL and #SLL results from the BRUIN study of pirtobrutinib. ORR in pts who previously received a BTKi was 74%. 2% of pts discontinued due to TEAE. 12mo estimated PFS rate was 68%.
#lymsm #medicalcongress
12 Dec 2022
CONGRESS | #ASH22 Tae Min Kim, MD @love_snuh presents data from the phase II ELM-2 trial of odronextamab in pts with R/R #FL Grade 1-3a. 75% of pts achieved CR by ICR. Safety profile was acceptable and in line with previous studies.
#lymsm #medicalcongress #hematology
#lymsm #medicalcongress #hematology
12 Dec 2022
CONGRESS | #ASH22 Catherine S. Diefenbach @Perlmutter_CC presents data from the phase Ib/II study of Pola-G-Len in pts with R/R #FL. The best overall response rate was 91%, with a best CR rate of 72%. After a median follow-up of 43.3 months, median PFS was not reached. #lymsm
12 Dec 2022
CONGRESS | #ASH22
@chanyooncheah, @uwanews presented data from the first in-human phase I trial of BGB-11417. BGB-11417 is more potent and selective than venetoclax. No pts discontinued due to AEs. 33% CR rate in pts treated with BGB-11417 monotherapy.
#lymsm #medicalcongress
@chanyooncheah, @uwanews presented data from the first in-human phase I trial of BGB-11417. BGB-11417 is more potent and selective than venetoclax. No pts discontinued due to AEs. 33% CR rate in pts treated with BGB-11417 monotherapy.
#lymsm #medicalcongress
12 Dec 2022
CONGRESS | #ASH22 @Kersten_MJ @CancerCenterAms presents data from the phase II HOVON110/ReBeL trial of R2 or R2 + bendamustine in pts with R/R #FL. Both regimens demonstrated high ORR and PET CMR rates. The results support ongoing R2 combination studies in FL.
#lymsm #hematology
#lymsm #hematology
12 Dec 2022
CONGRESS | ASH22
@drkomanduri discusses the risk of CRS with glofitamab as predicted by an updated prediction model. In aggressive histologies, the CRS-RS.5p model showed identical performance with the previous CRS-RS model & may be used to inform clinical decision making #lymsm
@drkomanduri discusses the risk of CRS with glofitamab as predicted by an updated prediction model. In aggressive histologies, the CRS-RS.5p model showed identical performance with the previous CRS-RS model & may be used to inform clinical decision making #lymsm
12 Dec 2022
CONGRESS | #ASH22
@NGhoshMD of @LevineCancer delivered final analysis results from the InfromCLL registry on real-world outcomes with 1L Ibr vs CIT in pts with CLL/SLL. 1L Ibr was linked with longer TTNT than CIT in pts, with sustained benefits up to 4 years of follow-up. #lymsm
@NGhoshMD of @LevineCancer delivered final analysis results from the InfromCLL registry on real-world outcomes with 1L Ibr vs CIT in pts with CLL/SLL. 1L Ibr was linked with longer TTNT than CIT in pts, with sustained benefits up to 4 years of follow-up. #lymsm
12 Dec 2022
CONGRESS | #ASH22 @AbdelWahablab @MSKCancerCenter shares interesting data on kinase dead BTK mutations that confer resistance to BTK inhibitors, yet are susceptible to clinical stage BTK degraders in #CLL patients
#lymsm #medicalcongress #hematology
#lymsm #medicalcongress #hematology
12 Dec 2022
CONGRESS | #ASH22 @LizSchorb @UniFreiburg discusses results from a phase II trial where the efficacy of autologous stem cell transplantation was demonstrated in patients >65 years with newly diagnosed PCNSL. Survival rates were comparable to younger cohorts. #lymsm
12 Dec 2022
CONGRESS | #ASH22 @NicolaisRobert @MSKCancerCenter presents an extended follow-up of short-course BV-AVD followed by RT in newly diagnosed #HL. Baseline MTV and PET2 were significantly associated with PFS. The regimen remains highly active at 4 years #lymsm #medicalcongress
12 Dec 2022
CONGRESS | #ASH22 Zachary R Hunter, @DanaFarber presents a multi-omic analysis of 253 untreated pts with #WM, revealing three distinct subtypes and a model for disease progression. This may provide a framework for further multi-omic study and targeted treatment approaches. #lymsm
12 Dec 2022
Keep an eye on our Twitter page!
The @lymphomahub will be bringing you comprehensive updates as we continue our live coverage of #ASH22.
Sessions covered today:
-Oral abstracts 621, 624, 626, 641, 642, 905
-Selected poster abstracts
#hematology #medicalcongress
The @lymphomahub will be bringing you comprehensive updates as we continue our live coverage of #ASH22.
Sessions covered today:
-Oral abstracts 621, 624, 626, 641, 642, 905
-Selected poster abstracts
#hematology #medicalcongress
12 Dec 2022
CONGRESS | #ASH22 @rsbhansaliMD @PennCancer speaks about the CNS relapse in T-cell lymphoma index (CITI), which can be used to predict CNS relapse in patients with T-cell #lymphoma. The data may be used to inform clinical decision making.
#lymsm #medicalcongress #hematology
#lymsm #medicalcongress #hematology
11 Dec 2022
CONGRESS | #ASH22 @falchi_lorenzo, @MSKCancerCenter presents initial results from the phase I/II trial of subcutaneous epcoritamab + R2 as first-line treatment for #FL. The combination demonstrated a manageable safety profile and encouraging efficacy, supporting further study
11 Dec 2022
CONGRESS | #ASH22 @nancybartlettMD @SitemanCenter presents updated results from the phase II study of mosunetuzumab in patients with R/R #FL. After a median follow-up of 27 months, durable responses continued to be observed with a safety profile in line with previous reports.
11 Dec 2022
CONGRESS | #ASH22 @falchi_lorenzo, @MSKCancerCenter presents an update from the phase I/II EPCORE NHL-2 trial of epcoritamab with R2 in patients with R/R #FL. The combination showed potent anti-tumor activity and a manageable safety profile with no new safety signals observed
11 Dec 2022
CONGRESS | #ASH22 Martin Dreyling, MD @LMU_Muenchen shares updated long-term data from the ELARA trial of tisagenlecleucel in R/R #FL. Robust responses were sustained >2 years post infusion, with a continued favourable safety profile #lymsm #medicalcongress #hematology
11 Dec 2022
CONGRESS | #ASH22 Jeremy Abramson, MD @MGHCancerCenter presents data on liso-cel vs SOC + salvage chemo + ASCT as 2L treatment in patients with R/R LBCL (TRANSFORM study). Liso-cel demonstrated statistically significant benefits to EFS, CR rate and PFS.
#lymsm #medicalcongress
#lymsm #medicalcongress
11 Dec 2022
CONGRESS | #ASH22 Martin Dreyling, MD @LMU_Muenchen presents results from the phase III TRIANGLE trial. The addition of ibrutinib with or without ASCT was associated with strong efficacy and acceptable toxicity, supporting the use of ibrutinib in younger patients with #MCL #lymsm
11 Dec 2022
Standing room only at the #ASH22 plenary session presenting the highest-caliber scientific abstracts at this years meeting. Martin Dreyling @LMU_Muenchen presents on the Triangle study of ibrutinib with standard therapy +/- ASCT for frontline treatment of #MCL #lymsm
11 Dec 2022
CONGRESS| #ASH22 @KathrynTringale, @MSKCancerCenter gave insights into factors impacting consolidation strategy and survival outcomes, as well as patterns of disease relapse in a large cohort of pts treated for primary CNS #lymphoma
#lymsm #medicalcongress
#lymsm #medicalcongress
11 Dec 2022
CONGRESS | #ASH22
Alex F. Herrera discussed data from the POLARIX study, on association of ctDNA levels and OS in pts with DLBCL. Pts were randomised to Pola-R-CHP or R-CHOP. Pts achieving a greater reduction in ctDNA after one cycle had longer OS and PFS.
#lymsm #hematology
Alex F. Herrera discussed data from the POLARIX study, on association of ctDNA levels and OS in pts with DLBCL. Pts were randomised to Pola-R-CHP or R-CHOP. Pts achieving a greater reduction in ctDNA after one cycle had longer OS and PFS.
#lymsm #hematology
11 Dec 2022
CONGRESS| #ASH22
Ajay Major, @UCCancerCenter shares results on the impact of checkpoint inhibitors on response rates, toxicity, and survival outcomes following CAR-T-cell relapse in pts with B-cell #lymphoma, using data from a large real-world multicenter cohort
#lymsm
Ajay Major, @UCCancerCenter shares results on the impact of checkpoint inhibitors on response rates, toxicity, and survival outcomes following CAR-T-cell relapse in pts with B-cell #lymphoma, using data from a large real-world multicenter cohort
#lymsm
11 Dec 2022
CONGRESS | #ASH22
@StefanoLuminari discussed the prognostic effect of baseline TMTV in pts with FL, from the FOLL12 study. In pts with high TMTV, 5-year PFS was significantly lower. Presence of FLIPI2 can effect the PFS and OS in subgroups of pts at high risk.
#lymsm #hematology
@StefanoLuminari discussed the prognostic effect of baseline TMTV in pts with FL, from the FOLL12 study. In pts with high TMTV, 5-year PFS was significantly lower. Presence of FLIPI2 can effect the PFS and OS in subgroups of pts at high risk.
#lymsm #hematology
11 Dec 2022
Secondary analyses revealed bispecific Abs as an effective treatment that could improve outcomes within this patient subset #ASH22 #medicalcongress
11 Dec 2022
CONGRESS| #ASH22
Federico Erbella, @HopSaintLouis delivers results on pts with R/R aggressive B-cell #lymphoma from the DESCAR-T registry who had late failures of CAR-T therapies. Data showed dismal outcomes amongst this patient subset #lymsm #medicalcongress
Federico Erbella, @HopSaintLouis delivers results on pts with R/R aggressive B-cell #lymphoma from the DESCAR-T registry who had late failures of CAR-T therapies. Data showed dismal outcomes amongst this patient subset #lymsm #medicalcongress
11 Dec 2022
CONGRESS | #ASH22
Won-Seog Kim presented results from the ELM-2 study, of heavily pre-treated pts with DLBCL treated with odronextamab. ORR was 49.2, with 66.4% 12 month duration of CR. CRS was the most common AE, with no grade 4 or 5 CRS.
#lymsm #medicalcongress #hematology
Won-Seog Kim presented results from the ELM-2 study, of heavily pre-treated pts with DLBCL treated with odronextamab. ORR was 49.2, with 66.4% 12 month duration of CR. CRS was the most common AE, with no grade 4 or 5 CRS.
#lymsm #medicalcongress #hematology
11 Dec 2022
CONGRESS | #ASH22
@ab_pau, @Hemato_Vhebron shared results from a study of epcoritamab, a bispecific Ab in combo with salvage immunochemotherapy in pts with R/R DLBCL eligible for ASCT. Pts enrolled were highly refractory. CR of 67% was observed. Median OS was not met.
#lymsm
@ab_pau, @Hemato_Vhebron shared results from a study of epcoritamab, a bispecific Ab in combo with salvage immunochemotherapy in pts with R/R DLBCL eligible for ASCT. Pts enrolled were highly refractory. CR of 67% was observed. Median OS was not met.
#lymsm
11 Dec 2022
CONGRESS | #ASH22
Caron A Jacobson presented results from a pilot study of axi-cel in 9 pts with R/R CNSL. CR rate of 67% with acceptable safety was observed. Med time to best response was 3 months.
#lymsm #medicalcongress #hematology
Caron A Jacobson presented results from a pilot study of axi-cel in 9 pts with R/R CNSL. CR rate of 67% with acceptable safety was observed. Med time to best response was 3 months.
#lymsm #medicalcongress #hematology
11 Dec 2022
CONGRESS | #ASH22
@DocHutchings discussed use of glofitamab in pts with R/R LBCL. 35.4% of pts achieved CR. 79% of pts in CR at EOT remained in CR at 2 years. One pt experienced progression at 12 month follow up post-EOT.
#lymsm #medicalcongress #hematology
@DocHutchings discussed use of glofitamab in pts with R/R LBCL. 35.4% of pts achieved CR. 79% of pts in CR at EOT remained in CR at 2 years. One pt experienced progression at 12 month follow up post-EOT.
#lymsm #medicalcongress #hematology
10 Dec 2022
CONGRESS | #ASH22
@niravshahmd, @MedicalCollege discussed results from a cohort of pts with Richter transformation in the BRUIN study. Treatment with pirtobrutinib was well tolerated with a med OS of 13.1mo. There was a low rate of Grade 3 or higher TEAE.
#lymsm #medicalcongress
@niravshahmd, @MedicalCollege discussed results from a cohort of pts with Richter transformation in the BRUIN study. Treatment with pirtobrutinib was well tolerated with a med OS of 13.1mo. There was a low rate of Grade 3 or higher TEAE.
#lymsm #medicalcongress
10 Dec 2022
CONGRESS | #ASH22
Arnon P. Kater, @amsterdamumc shared early results of the EPCORE Cll-1 trial of epcortitamab, a BsAb, in Richter's syndrome. No pts dicontinued due to TEAEs. An ORR of 60% and CR of 50% was observed.
#lymsm #medicalcongress #hematology
Arnon P. Kater, @amsterdamumc shared early results of the EPCORE Cll-1 trial of epcortitamab, a BsAb, in Richter's syndrome. No pts dicontinued due to TEAEs. An ORR of 60% and CR of 50% was observed.
#lymsm #medicalcongress #hematology
10 Dec 2022
CONGRESS l #ASH22
@clementinesar from @institut_curie summarizes that changes in the composition of the tumour microenvironment reveal a CD8+/LAG3+ clonal population with potential utility as a marker of transformation risk #lymsm
@clementinesar from @institut_curie summarizes that changes in the composition of the tumour microenvironment reveal a CD8+/LAG3+ clonal population with potential utility as a marker of transformation risk #lymsm
10 Dec 2022
CONGRESS l #ASH22
@clementinesar @institut_curie describes paired patients with fully divergent evolution, with unique genetic clones at DLBCL. Differential clonal expansion occurs - expansion of precursor cells present at diagnosis to novel clones emergent at transformation
@clementinesar @institut_curie describes paired patients with fully divergent evolution, with unique genetic clones at DLBCL. Differential clonal expansion occurs - expansion of precursor cells present at diagnosis to novel clones emergent at transformation
10 Dec 2022
CONGRESS l #ASH22
@clementinesar @institut_curie describes non-uniform clonal evolution identified across transformed FL pairs, with mixed FL and DLCBL clones in 3 pairs, with fully divergent clonal expansion in 5 pairs, and mixed BUT unique DLCBL clones in 3 pairs #lymsme
@clementinesar @institut_curie describes non-uniform clonal evolution identified across transformed FL pairs, with mixed FL and DLCBL clones in 3 pairs, with fully divergent clonal expansion in 5 pairs, and mixed BUT unique DLCBL clones in 3 pairs #lymsme
10 Dec 2022
CONGRESS l #ASH22
@clementinesar @institut_curie presents a single-cell, phylogenetic data analysis from 11 patients with transformed FL patients (paired FL/DLB-CL) with indolent FL controls, with bendustamine (n=125) and CVP (n=154) treated cohorts, both with rituximab
@clementinesar @institut_curie presents a single-cell, phylogenetic data analysis from 11 patients with transformed FL patients (paired FL/DLB-CL) with indolent FL controls, with bendustamine (n=125) and CVP (n=154) treated cohorts, both with rituximab
10 Dec 2022
CONGRESS | #ASH22
Paolo Ghia presented a poster on use of 1st line ibrutinib in pts with CLL. Data were pooled from 3 studies in pts with previously untreated CLL. 3 and 5 year estimated OS was significantly higher in pts treated with long-term ibrutinib vs CT.
#medicalcongress
Paolo Ghia presented a poster on use of 1st line ibrutinib in pts with CLL. Data were pooled from 3 studies in pts with previously untreated CLL. 3 and 5 year estimated OS was significantly higher in pts treated with long-term ibrutinib vs CT.
#medicalcongress
10 Dec 2022
CONGRESS l #ASH22
@perretmegan, @QMBCI describes high numbers of tumor-infiltrating CD4+ cells in non-transformed FL, compared to high levels of CD8+ with transformation. Single-cell analysis can identify novel clonal changes in patients at different stages of FL transformation
@perretmegan, @QMBCI describes high numbers of tumor-infiltrating CD4+ cells in non-transformed FL, compared to high levels of CD8+ with transformation. Single-cell analysis can identify novel clonal changes in patients at different stages of FL transformation
10 Dec 2022
CONGRESS l #ASH22
@perretmegan, @QMBCI explains copy number alterations and B-cell receptor anomalies were not dominant drivers of aggressive phenotypes. Increased interferon-memory and plasma-like B-cell states were noted in malignant B-cells, influencing clinical phenotypes
@perretmegan, @QMBCI explains copy number alterations and B-cell receptor anomalies were not dominant drivers of aggressive phenotypes. Increased interferon-memory and plasma-like B-cell states were noted in malignant B-cells, influencing clinical phenotypes
10 Dec 2022
CONGRESS l #ASH22
@perretmegan from @QMBCI presents data from a longitudinal study of tumour microenvironment and tumour cells in patents with FL transforming from indolent to high-grade, aggressive DLB-CL. analysis of lymph node suspensions allowed profiling of over 110K cells
@perretmegan from @QMBCI presents data from a longitudinal study of tumour microenvironment and tumour cells in patents with FL transforming from indolent to high-grade, aggressive DLB-CL. analysis of lymph node suspensions allowed profiling of over 110K cells
10 Dec 2022
CONGRESS | #ASH22
Henriette Huber presented the final analysis of the CLL2-GIVe trial of pts with CLL with del(17p) and/or TP53 mutation. The triple combination treatment regimen used had an acceptable safety profile with a 36 month OS rate of 92.6%.
#medicalcongress #hematology
Henriette Huber presented the final analysis of the CLL2-GIVe trial of pts with CLL with del(17p) and/or TP53 mutation. The triple combination treatment regimen used had an acceptable safety profile with a 36 month OS rate of 92.6%.
#medicalcongress #hematology
10 Dec 2022
CONGRESS | #ASH22
Sandeep Raj, MD @MSKCancerCenter discusses inflammatory biomarker clusters in relation to #LBCL treated with CAR-T. He showed how these clusters are predictive of response and toxicity in this setting.
#lymsm #medicalcongress #hematology
Sandeep Raj, MD @MSKCancerCenter discusses inflammatory biomarker clusters in relation to #LBCL treated with CAR-T. He showed how these clusters are predictive of response and toxicity in this setting.
#lymsm #medicalcongress #hematology
10 Dec 2022
CONGRESS | #ASH22
@HouotRoch, @CHURennes presents a primary analysis of the phase II ALYCANTE study of axi-cel in transplant ineligible #LBCL patients. The study met its primary endpoints, with axi-cel appearing to be a safe and efficacious therapy for this patient group. #lymsm
@HouotRoch, @CHURennes presents a primary analysis of the phase II ALYCANTE study of axi-cel in transplant ineligible #LBCL patients. The study met its primary endpoints, with axi-cel appearing to be a safe and efficacious therapy for this patient group. #lymsm
10 Dec 2022
CONGRESS | #ASH22
@HouotRoch, @CHURennes presents a primary analysis of the phase II LYSA study of axi-cel in transplant ineligible #LBCL patients. The study met its primary endpoints, with axi-cel appearing to be a feasible and efficacious therapy for this patient group. #lymsm
@HouotRoch, @CHURennes presents a primary analysis of the phase II LYSA study of axi-cel in transplant ineligible #LBCL patients. The study met its primary endpoints, with axi-cel appearing to be a feasible and efficacious therapy for this patient group. #lymsm
10 Dec 2022
CONGRESS | #ASH22
@OpatStephen @MonashHealth presents final analysis from the MAGNOLIA trial of zanubrutinib in patients with R/R #MZL. The results indicate strong long-term efficacy, indicated by high response rates durable disease control, and a favourable safety profile
#lymsm
@OpatStephen @MonashHealth presents final analysis from the MAGNOLIA trial of zanubrutinib in patients with R/R #MZL. The results indicate strong long-term efficacy, indicated by high response rates durable disease control, and a favourable safety profile
#lymsm
10 Dec 2022
CONGRESS | #ASH22
@c_thieblemont of @HopSaintLouis presents early results from the phase I/II study of iberdomide ± rituximab/obinutuzumab in R/R #lymphoma. Iberdomide alone and in combination with anti-CD20 mAbs showed promising activity in this patient group.
#lymsm
@c_thieblemont of @HopSaintLouis presents early results from the phase I/II study of iberdomide ± rituximab/obinutuzumab in R/R #lymphoma. Iberdomide alone and in combination with anti-CD20 mAbs showed promising activity in this patient group.
#lymsm
10 Dec 2022
CONGRESS | #ASH22
Jorge J. Castillo, @DanaFarber shares insights into ibrutinib and venetoclax in previously untreated #WM. The combination was associated with a major response rate of 93%, and a VGPR rate of 40%. However, the study finished early due to safety concerns.
#lymsm
Jorge J. Castillo, @DanaFarber shares insights into ibrutinib and venetoclax in previously untreated #WM. The combination was associated with a major response rate of 93%, and a VGPR rate of 40%. However, the study finished early due to safety concerns.
#lymsm
10 Dec 2022
CONGRESS | #ASH22
@JohnPLeonardMD, @nyphospital @WeillCornell presents five-year results and overall survival update from the AUGMENT trial of R2 vs R-placebo in patients with R/R indolent #nHL. R2 continues to demonstrate superior efficacy, consistent with previous data.
#lymsm
@JohnPLeonardMD, @nyphospital @WeillCornell presents five-year results and overall survival update from the AUGMENT trial of R2 vs R-placebo in patients with R/R indolent #nHL. R2 continues to demonstrate superior efficacy, consistent with previous data.
#lymsm
10 Dec 2022
CONGRESS | #ASH22
@LiaPalomba @MSKCancerCenter discusses results of the phase I/II BRUIN study of the BTK inhibitor pirtobrutinib in R/R #WM. The drug was shown to be highly active and well-tolerated, irrespective of prior therapy status. #lymsm #medicalcongress #hematology
@LiaPalomba @MSKCancerCenter discusses results of the phase I/II BRUIN study of the BTK inhibitor pirtobrutinib in R/R #WM. The drug was shown to be highly active and well-tolerated, irrespective of prior therapy status. #lymsm #medicalcongress #hematology
10 Dec 2022
CONGRESS | #ASH22
@gloria_iacoboni discussed early progression in pts with LBCL after CAR-T therapy. Salvage therapies produced a higher response than chemotherapy. Polatuzumab regimens yielded the highest response rates.
#lymsm #medicalcongress #hematology
@gloria_iacoboni discussed early progression in pts with LBCL after CAR-T therapy. Salvage therapies produced a higher response than chemotherapy. Polatuzumab regimens yielded the highest response rates.
#lymsm #medicalcongress #hematology
10 Dec 2022
CONGRESS | #ASH22
Edward Poyton shared results from a retrospective study on the prognostic value of BCL-2, BCL-6 and MYC expression in PCNSL. Double expression was associated with significantly poorer PFS.
#lymsm #medicalcongress #hematology
Edward Poyton shared results from a retrospective study on the prognostic value of BCL-2, BCL-6 and MYC expression in PCNSL. Double expression was associated with significantly poorer PFS.
#lymsm #medicalcongress #hematology
10 Dec 2022
CONGRESS | #ASH22
@Talha Munir, @LIMRLeeds presents an updated interim analysis of the phase III FLAIR study. Ibrutinib + venetoclax was shown to induce high rates of MRD-negativity in both IGHV mutated and unmutated #CLL
#lymsm #medicalcongress #hematology
@Talha Munir, @LIMRLeeds presents an updated interim analysis of the phase III FLAIR study. Ibrutinib + venetoclax was shown to induce high rates of MRD-negativity in both IGHV mutated and unmutated #CLL
#lymsm #medicalcongress #hematology
10 Dec 2022
CONGRESS | #ASH22
@carsten_niemann, @Rigshospitalet presents follow-up data from the GLOW study on residual disease kinetics among pts with high-risk factors treated Ibr+Ven vs Clb+O. The Ibr+Ven combination achieved superior uMRD responses.
#lymsm #medicalcongress #hematology
@carsten_niemann, @Rigshospitalet presents follow-up data from the GLOW study on residual disease kinetics among pts with high-risk factors treated Ibr+Ven vs Clb+O. The Ibr+Ven combination achieved superior uMRD responses.
#lymsm #medicalcongress #hematology
10 Dec 2022
CONGRESS | #ASH22
John N. Allan of @WCM_MeyerCancer presents a 5-year follow-up of the phase II CAPTIVATE trial of Ibr +Ven in patients with #CLL. The results further support the use of this treatment protocol based on the favorable benefit-risk profile.
#lymsm #medicalcongress
John N. Allan of @WCM_MeyerCancer presents a 5-year follow-up of the phase II CAPTIVATE trial of Ibr +Ven in patients with #CLL. The results further support the use of this treatment protocol based on the favorable benefit-risk profile.
#lymsm #medicalcongress
10 Dec 2022
CONGRESS | #ASH22
@Mjerkeman @lunduniversity presents data on the phase Ib/II VALERIA trial of venetoclax, lenalidomide and rituximab combination therapy for the treatment of R/R #MCL. The results show this combination therapy to be tolerable and efficacious.
#lymsm #hematology
@Mjerkeman @lunduniversity presents data on the phase Ib/II VALERIA trial of venetoclax, lenalidomide and rituximab combination therapy for the treatment of R/R #MCL. The results show this combination therapy to be tolerable and efficacious.
#lymsm #hematology
10 Dec 2022
CONGRESS | #ASH22
@AdrianMinson, @UniMelb @PeterMacCC shares data from the first of its kind TARMAC study of ibrutinib + tisagenlecleucel in R/R #MCL. The data indicate this is a safe and highly effective treatment option for this patient population.
#lymsm #medicalcongress
@AdrianMinson, @UniMelb @PeterMacCC shares data from the first of its kind TARMAC study of ibrutinib + tisagenlecleucel in R/R #MCL. The data indicate this is a safe and highly effective treatment option for this patient population.
#lymsm #medicalcongress
10 Dec 2022
CONGRESS | #ASH22
@LymphClinician of @umichmedicine shares data on glofitamab monotherapy in patients with R/R #MCL. Glofitamab was shown to induce high and durable CR rates with an acceptable safety profile. Most CRS events were manageable and of low-grade.
#lymsm
@LymphClinician of @umichmedicine shares data on glofitamab monotherapy in patients with R/R #MCL. Glofitamab was shown to induce high and durable CR rates with an acceptable safety profile. Most CRS events were manageable and of low-grade.
#lymsm
10 Dec 2022
CONGRESS | #ASH22
Jia Ruan MD, of @WCM_MeyerCancer, presents data from a phase II trial of acalabrutinib-lenalidomide-rituximab in patients with treatment-naïve #MCL. The combination was well tolerated, highly effective, and produced high rates of MRD-negativity.
#lymsm
Jia Ruan MD, of @WCM_MeyerCancer, presents data from a phase II trial of acalabrutinib-lenalidomide-rituximab in patients with treatment-naïve #MCL. The combination was well tolerated, highly effective, and produced high rates of MRD-negativity.
#lymsm
10 Dec 2022
#ASH22 starts today!
The @lymphomahub will be covering ASH virtually and in person.
Keep an eye on our Twitter page for live updates, key insights, and interview coverage!
#hematology #lymsm
The @lymphomahub will be covering ASH virtually and in person.
Keep an eye on our Twitter page for live updates, key insights, and interview coverage!
#hematology #lymsm
9 Dec 2022
The @lymphomahub will be covering the 64th ASH Annual Meeting & Exposition!
🗓 Date: Dec 10–13
📍 Location: New Orleans and online
Keep an eye on our socials for live coverage throughout the day from our virtual and in-person attendance!
#ASH22 #hematology #lymsm
🗓 Date: Dec 10–13
📍 Location: New Orleans and online
Keep an eye on our socials for live coverage throughout the day from our virtual and in-person attendance!
#ASH22 #hematology #lymsm
6 Dec 2022
Get ready for #ASH22 with us!
The list of top abstracts selected by our steering committee for the 64th @ASH_hematology Annual Meeting and Exposition is now available on the @lymphomahub!
📌Find out more: https://t.co/9YZttsf9Wi
#ASH2022 #lymsm #medicaljournal #cancer
The list of top abstracts selected by our steering committee for the 64th @ASH_hematology Annual Meeting and Exposition is now available on the @lymphomahub!
📌Find out more: https://t.co/9YZttsf9Wi
#ASH2022 #lymsm #medicaljournal #cancer
30 Nov 2022
To help navigate the exciting content being presented at #ASH22, our steering committee members have provided their top abstracts to keep an eye out for in #lymphoma and #CLL. Check them out here 👉 https://t.co/9YZttsf9Wi. #medicalcongress
<span> </span>
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.
Your opinion matters
When selecting the next therapy for patients with R/R MCL after BTKi progression, what is your most important consideration?